Defilade Capital Management, L.P.
13F Reported Value
ⓘ$712.2M
Holdings
31
Latest Filing
2026-03-31
Filing Quarter
Q1 2026
Portfolio Overview
Defilade Capital Management, L.P. disclosed 31 positions worth $712.2M in its Form 13F-HR for Q1 2026, led by $ZBH (ZIMMER BIOMET HOLDINGS, INC.) at 7.3% of the equity portfolio, followed by $HSIC and $BDX. During the quarter the fund opened 9 new positions and exited 11 — including a new stake in $ZBH and a full exit from $ABBV. The portfolio is most concentrated in Healthcare (100.0% of disclosed assets). All figures are sourced directly from Defilade Capital Management, L.P.’s Form 13F-HR filing with the SEC under CIK 2088557.
Sector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q1 2026
Click any card to unlockTop Holdings
- 64.9#606
Quality
$52.4M579,161 sh - 52.0#1,368
Quality
$46.0M624,037 sh - 50.7#1,437
Quality
$43.9M279,210 sh - 80.0
Quality
$41.1M376,165 sh - 77.9
Quality
$33.8M538,762 sh - 40.5
Quality
$32.8M254,291 sh - 29.4
Quality
$31.9M194,909 sh - 81.4
Quality
$31.2M67,681 sh - —
Quality
$30.7M315,972 sh - 77.6
Quality
$30.5M354,350 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 ZIMMER BIOMET HOLDINGS, INC.$ZBH | 64.9#606 | $52.4M | 579,161 |
 HENRY SCHEIN INC$HSIC | 52.0#1,368 | $46.0M | 624,037 |
 BECTON DICKINSON & CO$BDX | 50.7#1,437 | $43.9M | 279,210 |
 PTC THERAPEUTICS, INC.$PTCT | 80.0 | $41.1M | 376,165 |
 DEXCOM INC$DXCM | 77.9 | $33.8M | 538,762 |
 ICU MEDICAL INC/DE$ICUI | 40.5 | $32.8M | 254,291 |
 INSMED Inc$INSM | 29.4 | $31.9M | 194,909 |
 INTUITIVE SURGICAL INC$ISRG | 81.4 | $31.2M | 67,681 |
 Revolution Medicines, Inc.$RVMD | — | $30.7M | 315,972 |
 GLOBUS MEDICAL INC$GMED | 77.6 | $30.5M | 354,350 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of Defilade Capital Management, L.P.'s 31 positions.
Showing top 10 of 31 holdings.
Sector Allocation
Healthcare
$712.2M
Full Holdings — Defilade Capital Management, L.P. (Q1 2026)
All 31 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $ZBH | ZIMMER BIOMET HOLDINGS, INC. | $52.4M | 7.3% | NEW | 64.9 |
| 2 | $HSIC | HENRY SCHEIN INC | $46.0M | 6.5% | +95% | 52 |
| 3 | $BDX | BECTON DICKINSON & CO | $43.9M | 6.2% | +244% | 50.7 |
| 4 | $PTCT | PTC THERAPEUTICS, INC. | $41.1M | 5.8% | NEW | 80 |
| 5 | $DXCM | DEXCOM INC | $33.8M | 4.8% | +120% | 77.9 |
| 6 | $ICUI | ICU MEDICAL INC/DE | $32.8M | 4.6% | -25% | 40.5 |
| 7 | $INSM | INSMED Inc | $31.9M | 4.5% | +290% | 29.4 |
| 8 | $ISRG | INTUITIVE SURGICAL INC | $31.2M | 4.4% | +48% | 81.4 |
| 9 | $RVMD | Revolution Medicines, Inc. | $30.7M | 4.3% | -13% | — |
| 10 | $GMED | GLOBUS MEDICAL INC | $30.5M | 4.3% | +33% | 77.6 |
| 11 |  $NBIX | NEUROCRINE BIOSCIENCES INC | $27.7M | 3.9% | NEW | 75.4 |
| 12 |  $DNLI | Denali Therapeutics Inc. | $26.1M | 3.7% | +107% | — |
| 13 |  $PACS | PACS Group, Inc. | $25.6M | 3.6% | -47% | 70.4 |
| 14 |  $OLMA | Olema Pharmaceuticals, Inc. | $22.4M | 3.1% | +22% | — |
| 15 |  $ELAN | Elanco Animal Health Inc | $22.3M | 3.1% | +132% | 52.2 |
| 16 |  $PFE | PFIZER INC | $19.4M | 2.7% | -34% | 69 |
| 17 |  $LLY | ELI LILLY & Co | $19.0M | 2.7% | -35% | 89.3 |
| 18 |  $LNTH | Lantheus Holdings, Inc. | $18.9M | 2.7% | NEW | 66.9 |
| 19 |  $ITGR | Integer Holdings Corp | $18.7M | 2.6% | NEW | 50.2 |
| 20 |  $BIIB | BIOGEN INC. | $17.7M | 2.5% | -41% | 65.6 |
| 21 |  $EVMN | Evommune, Inc. | $15.6M | 2.2% | +215% | — |
| 22 |  $TNDM | TANDEM DIABETES CARE INC | $14.6M | 2.0% | NEW | 34.8 |
| 23 |  $COGT | Cogent Biosciences, Inc. | $13.6M | 1.9% | -38% | — |
| 24 |  $NUVL | Nuvalent, Inc. | $13.3M | 1.9% | -52% | — |
| 25 |  $OCUL | OCULAR THERAPEUTIX, INC | $12.6M | 1.8% | +118% | 12.8 |
| 26 |  $ASND | Ascendis Pharma A/S | $11.9M | 1.7% | -39% | 41.5 |
| 27 |  $ALGN | ALIGN TECHNOLOGY INC | $11.5M | 1.6% | -47% | 58.2 |
| 28 |  $ELDN | Eledon Pharmaceuticals, Inc. | $11.0M | 1.5% | +8% | — |
| 29 |  $ORIC | Oric Pharmaceuticals, Inc. | $10.7M | 1.5% | NEW | — |
| 30 |  $BHVN | Biohaven Ltd. | $2.7M | 0.4% | NEW | — |
| 31 |  $MREO | Mereo BioPharma Group plc | $2.5M | 0.3% | NEW | — |
New Positions (9)
$ZBH ZIMMER BIOMET HOLDINGS, INC.$52.4M$PTCT PTC THERAPEUTICS, INC.$41.1M$NBIX NEUROCRINE BIOSCIENCES INC$27.7M$LNTH Lantheus Holdings, Inc.$18.9M$ITGR Integer Holdings Corp$18.7M$TNDM TANDEM DIABETES CARE INC$14.6M$ORIC Oric Pharmaceuticals, Inc.$10.7M$BHVN Biohaven Ltd.$2.7M$MREO Mereo BioPharma Group plc$2.5M
Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for Defilade Capital Management, L.P. including:
Track Defilade Capital Management, L.P.'s Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for Defilade Capital Management, L.P. and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: Defilade Capital Management, L.P.
13F Pro is an AI hedge fund tracker and stock research platform. For Defilade Capital Management, L.P. (SEC CIK: 2088557), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Defilade Capital Management, L.P.'s portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.